Tokyo - Delayed Quote JPY

Nippon Shinyaku Co., Ltd. (4516.T)

3,340.00 -133.00 (-3.83%)

At close: November 6 at 3:30:00 PM GMT+9

Nippon Shinyaku (TSE:4516) Stock Looks Fairly Valued At Current Levels

Simply Wall St. 20d ago

4516.T
-3.83%
4516
NS Pharma Parent Company, Nippon Shinyaku, Exercises Option Rights for Commercialization of AB2 BIO's Tadekinig alfa in the U.S.

PR Newswire 3mo ago

4516.T
-3.83%
AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa

GlobeNewswire 3mo ago

4516.T
-3.83%
Nippon Shinyaku and Elixirgen Therapeutics Enter Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy

PR Newswire 4mo ago

4516.T
-3.83%
Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy

GlobeNewswire 4mo ago

4516.T
-3.83%
NS Pharma Parent Company, Nippon Shinyaku, Announces Sponsored Research Agreement with Boston Children's Hospital

PR Newswire 4mo ago

4516.T
-3.83%
ADC Therapeutics Announces ZYNLONTA® Updates in Japan

PR Newswire 9d ago

ADCT

4516.T
-3.83%
Regenxbio Shares Rise After Positive Duchenne Trial Results

InvestorsHub 5mo ago

RGNX

4516.T
-3.83%
Capricor Lawsuit Puts Duchenne Therapy Launch Plans And Valuation In Focus

Simply Wall St. 5mo ago

CAPR

4516.T
-3.83%
Capricor Therapeutics Q1 Earnings Call Highlights

MarketBeat 5mo ago

CAPR

4516.T
-3.83%
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire 5mo ago

CAPR

4516.T
-3.83%
All Eyes On Capricor Therapeutics Ahead Of Crucial Hearing On DMD Therapy Agreement – CAPR Stock Jumps 6%

Stocktwits 4mo ago

CAPR

4516.T
-3.83%

U.S. markets closed

Nippon Shinyaku Co., Ltd. (4516.T)

Nippon Shinyaku (TSE:4516) Stock Looks Fairly Valued At Current Levels

NS Pharma Parent Company, Nippon Shinyaku, Exercises Option Rights for Commercialization of AB2 BIO's Tadekinig alfa in the U.S.

AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa

Nippon Shinyaku and Elixirgen Therapeutics Enter Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy

Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy

NS Pharma Parent Company, Nippon Shinyaku, Announces Sponsored Research Agreement with Boston Children's Hospital

ADC Therapeutics Announces ZYNLONTA® Updates in Japan

Regenxbio Shares Rise After Positive Duchenne Trial Results

Capricor Lawsuit Puts Duchenne Therapy Launch Plans And Valuation In Focus

Capricor Therapeutics Q1 Earnings Call Highlights

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

All Eyes On Capricor Therapeutics Ahead Of Crucial Hearing On DMD Therapy Agreement – CAPR Stock Jumps 6%